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Introduction. The National Institute for Health and Clinical Excellence (NICE) guidance recommends that dyspeptic patients are
tested for Helicobacter pylori using a urea breath test, stool antigen test, or serology. Antibiotic resistance in H. pylori is globally
increasing, but treatment in England is rarely guided by susceptibility testing or surveillance. Aims. To determine compliance of
microbiology laboratories in England with NICE guidance and whether laboratories perform culture and antibiotic susceptibility
testing (AST). Methods. In 2015, 170 accredited English microbiology laboratories were surveyed, by email. Results. 121/170 (71%)
laboratories responded; 96% provided H. pylori testing (78% on site). 94% provided H. pylori diagnosis using stool antigen; only
four provided serology as their noninvasive test; 3/4 of these encouraged urea breath tests in their acute trusts. Only 22/94 (23%)
of the laboratories performed H. pylori cultures from gastric biopsies on site; 9/22 performed AST, but the vast majority processed
less than one specimen/week. Conclusions. Only five laboratories in England do not comply with NICE guidance; these will need
the guidance reinforced. National surveillance needs to be implemented; culture-based AST would need to be centralised. Moving
forward, detection of resistance in H. pylori from stool specimens using molecular methods (PCR) needs to be explored.
1. Introduction
Helicobacter pylori causes chronic active gastritis that may
be associated with symptomatic dyspepsia, which occurs in
over 10% of the UK adult population [1, 2]. Infection with
H. pylori is a cofactor in the development of duodenal and
gastric ulcers, gastric cancer, and gastric mucosa-associated
lymphoid-tissue (MALT) lymphoma [3, 4]. Nevertheless, the
great majority of patients with H. pylori infection will not
have any clinically significant complications [5].
“Test-and-Treat” forH. pylori is recommended for symp-
tomatic patients, as this strategy will cure most underlying
peptic ulcer diseases and prevent future H. pylori associ-
ated gastroduodenal disease [2]. However, many infected
patients with functional dyspepsia will not gain symptomatic
benefit [6]. Current guidance from the National Institute
for Health and Clinical Excellence (NICE) (Supplementary
1 in Supplementary Material available online at http://dx.doi
.org/10.1155/2016/8540904) recommends that clinicians offer
dyspeptic patients noninvasive H. pylori testing using a
carbon-13 urea breath test (UBT) or a stool antigen test (SAT),
or laboratory-based serology where its performance has been
locally validated [2].
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NICE recommends first-line treatment for H. pylori with
a proton-pump inhibitor (PPI) and two antibiotics (usually
amoxicillin and either clarithromycin or metronidazole),
choosing the treatment regimen with the lowest acquisition
cost, and taking into account previous exposure to clar-
ithromycin or metronidazole [2]. H. pylori treatment failure
usually indicates poor compliance or antibiotic resistance,
often acquired through antibiotic treatment for H. pylori or
another infection [4]. A European prospective study (2008-
2009) showed resistance rates of 17.5% for clarithromycin,
14.1% for levofloxacin, and 34.9% for metronidazole [7].
Routine surveillance of antibiotic resistance in H. pylori
could inform treatment recommendations and assess the
efficacy of public health strategies aiming to control antibiotic
resistance.
This audit aimed to assess microbiology laboratory com-
pliance with NICE guidance for the noninvasive diagnosis of
H. pylori and to determine the number of laboratories under-
taking culture and antibiotic susceptibility testing (AST).
This data will be used to inform the need for enhanced
implementation of the NICE guidance and decisions on how
any future nationalH. pylori antibiotic resistance surveillance
systems could be set up across England.
2. Methods
2.1. Questionnaire Development. The draft survey was devel-
oped by microbiologists with an interest in the field and
piloted several times with five laboratories, for ease of com-
pletion and feasibility of data entry. The 14 survey questions
(Supplementary 2) asked about the different diagnostic tests
performed for H. pylori detection, including serology, stool
antigen, culture from gastric biopsies, AST, PCR, rapid
urease on biopsies and C14 breath tests, numbers performed
weekly/yearly, and typical positivity rates.
2.2. Participants. Questionnaires were sent by email, in 2015,
to 170 accredited microbiology laboratories in England. All
nonresponding laboratories were telephoned to check the
name and contact details of a suitable contact involved in H.
pylori testing. Nonresponders could also complete the ques-
tionnaire by telephone. To increase returns, questionnaires
were also circulated via Public Health England (PHE) labo-
ratory circulation lists. Participants were offered a certificate
to use towards their Continuing Professional Development
(CPD) as an incentive to complete the questionnaire.
2.3. Data Analysis. EpiData version 3.1 was used to input the
questionnaire data. Data was cleaned by one of the research
team. Where laboratories had ticked more than one box for
an answer, comments given by participants were used by
the researchers to determine which answer was counted and
resolve discordant results. Free text answers were discussed
by three researchers and assigned to categories.The question-
naire data was double entered by two separate researchers;
minor disagreements were resolved by referral to the original
questionnaire.The data was exported toMicrosoft Excel 2010
for data analysis. The number of responses and proportion
of different responses to each question were tabulated and
summary descriptive statistical analysis was carried out and
graphs were produced to display the data.
3. Ethics
This audit was undertaken to assess the need for routine
national surveillance for antimicrobial resistance and as such
did not require ethical approval. However, the audit was
undertaken in line with information governance.
4. Results and Discussion
Of the 121/170 (71%) laboratories that responded, 116/121
(96%) provided a H. pylori testing service: 94/121 (78%) of
which were performed on site and 22/121 (18%) referred
specimens to another laboratory (see Figure 1). Of the five
laboratories not providing a testing service, two reported that
their gastroenterologists performed urea breath tests.
4.1. Compliance with NICE Recommendations for the Diag-
nosis of Helicobacter pylori. Figure 2 shows that the results
of this audit are promising, as a vast majority of laboratories
(88/94, 94%) are providing stool antigen testing to diagnose
H. pylori, which is the laboratory diagnostic test recom-
mended in the NICE guidance [2]. However, there are still
four laboratories doing serology as their first-line noninvasive
diagnostic test, although three of these reported that they
encourage urea breath tests in their acute trusts.
4.2. Stool Antigen Tests. Thenumber ofH. pylori stool antigen
tests performed by each lab ranged from 2/week to 450/week,
with a mean of 88 tests/week (see Figure 3). Individual
laboratories reported positivity rates of between 1% and 33%
(mean 13%). There is a very large range in the positivity rate
for H. pylori stool antigen tests (Figure 3) indicating that
different patient groups are being tested in the centres with
high and low positivity. A high percentage of positive results
could be because either clinicians are only doing the test
after treatment failure or, alternatively, the population has
high ethnicity or deprivation, in which prevalence is higher
[4, 8–10]. To explore this, indices of multiple deprivation
(IMD, 2015) of the Clinical Commissioning Groups (CCGs)
served by each laboratory were examined, and no correlation
was found between positivity of H. pylori diagnosis by stool
antigen test and deprivation (𝑅2 = 0.0233). However, no data
on ethnicity was provided.
In some laboratories, the positivity rate of their stool
antigen tests was reported to be 3% or less (minimum of
1%), which is very low. False negative stool antigen or urea
breath tests can be obtained if a patient is still taking proton-
pump inhibitors or antibiotics when the test is performed, as
they can reduce numbers of H. pylori in the gastric mucosa
[11]. It is possible that, in these laboratories, patients were not
advised to take or did not stop taking proton-pump inhibitors
two weeks before, or antibiotics for 4 weeks before, the stool
antigen test (as advised in NICE guidance) [2, 11]. However,
you would expect noncompliance with this recommendation
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Figure 1: The number of laboratories offering various Helicobacter pylori diagnostic tests on site or through a referral service (𝑛 = 94).
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Figure 2: First-line diagnostic Helicobacter pylori tests performed on site by laboratories (𝑛 = 94).
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Figure 3: Average reported H. pylori stool antigen tests performed in-house each week with percentage positive results (𝑛 = 88).
to be similar throughout the country. Therefore, it is likely
that the varying positivity rate in labs represents either a
true variation in the H. pylori rate across England, which
would influence dyspepsia and ulcer rates, or a variation in
testing guidance for clinicians [4]. This needs to be further
investigated with more detailed epidemiological surveillance
comparing patient demographics and details of the clinical
indication for the test.
4.3. Serological Testing for H. pylori. Ten laboratories per-
formedH. pylori blood serology, six of whichwere in addition
to stool antigen testing. Three laboratories (3%) refer their
blood serology to other laboratories, and 77 laboratories
(82%) reported that they do not perform H. pylori blood
serology.On average, 48 tests were performed in the laborato-
ries each week and the percentage of positive H. pylori serol-
ogy tests reported by 6 laboratories ranged from 5% to 25%
with a mean of 13% positive. Three laboratories commented
that blood serology was only used as second-line therapy by
gastroenterologists for patients on Helicobacter suppressing
drugs such as PPI or for patients that had an active bleeding
ulcer. This is in line with National PHE guidance that advises
that serology is useful in patients with acute gastrointestinal
bleeding when blood and PPI use may interact with the UBT
or SAT [12].
4.4. PCR. Of the 94 laboratories that routinely test for H.
pylori, 1 laboratory (1%) performed H. pylori PCR tests in
their lab, 10 laboratories (11%) referred samples to other
laboratories (9 to the GBRU), and 78 laboratories (83%) do
not offer this service.
4.5. Urea Breath Test. Urea breath test is the most reliable
noninvasive test for H. pylori [13]. In the UK, unlike other
diagnostic tests, it needs to be prescribed, as the test involves
taking a capsule containing radiolabelled urea, 20 to 30
minutes before the breath test is performed, and then sent
to a central laboratory for analysis. Most laboratories did not
know whether urea breath tests (UBTs) were encouraged: in
their hospital setting (57%) or CCG (77%). Only 17 (18%)
laboratories reported thatUBTswere encouragedwithin their
acute trust and 7% reported that UBTs were encouraged by
their CCGs. It could be advised that laboratory staff should
discuss whether UBTs are encouraged by their gastroenterol-
ogists in the acute trust or community, as this could influence
what tests the laboratory should be providing or advising,
before and after H. pylori treatment.
4.6. Biopsy Urease and Culture of Biopsy Specimens. Almost
half of the laboratories, 46% (43/94), referred biopsy spec-
imens for culture to another laboratory: 39/43 (91%) to the
Gastrointestinal Bacteria Reference Unit (GBRU) in London.
40 laboratories (43%) performedH. pylori biopsy urease tests.
H. pylori cultures were performed on site by 22/94 labora-
tories. Three of the laboratories that performed cultures on
site also referred some specimens of cultures to the Reference
Unit.
Only two laboratories reported culturing a significant
number of gastric biopsy specimens forH. pylori (10 or more
gastric biopsies per week) and the other 20 performed it
occasionally (processing less than one biopsy culture weekly).
Seven laboratories commented that they rarely carried out
cultures of biopsy specimens; and another eight reported
that culture was only performed after treatment failure. The
two laboratories that performed more than ten specimens
reported their positivity as 7% and 30%.
4.7. Antibiotic Susceptibility. Of the 22 laboratories that per-
formed in-house cultures of biopsy, nine reported testing
for antibiotic susceptibility on site, and nine referred their
samples (8/9 referred to the GBRU). Four referred the biopsy
specimens, three referred culture isolates, and two referred
both biopsy specimens and culture isolates.
Of the nine laboratories that test for antibiotic susceptibil-
ity in-house, only one tested all five antibiotics listed as first-
or second-line therapy in NICE guidance (metronidazole,
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Table 1: Antibiotic susceptibility tests performed in-house by labo-
ratories (𝑛 = 8).
Agents tested Number of labs(%)
Number of labs performing
each test (can do both)
𝑒-test Disc.
Metronidazole 𝑛 = 7 (88%) 4 4
Clarithromycin 𝑛 = 6 (75%) 4 2
Amoxicillin 𝑛 = 7 (88%) 4 3
Tetracycline 𝑛 = 5 (63%) 4 1
Levofloxacin 𝑛 = 2 (25%) 1 1
clarithromycin, amoxicillin, tetracycline, and levofloxacin)
and only another one tested for levofloxacin [2] (see Table 1).
Themost recent data shows that the current combination
treatment has lost some efficacy with successful eradication
rates in about 70% of patients [14].H. pylori treatment failure
is often due to antibiotic resistance [3, 4, 15–17]. Despite this,
a surveillance system to monitor trends in resistance at a
local and national level does not currently exist in England.
The tailored treatment regimen chosen forH. pylori could be
based on culture and susceptibility testing of gastric biopsy
specimens from each individual patient [14, 15, 18–20]. How-
ever, this is not cost-effective in a country with low preva-
lence, such as England. Thus, NICE guidance recommends
Test-and-Treat forH. pylori using noninvasive tests for nonul-
cer dyspepsia [2, 21]. NICE guidance only recommends the
invasive approach of culture and susceptibility testing, after
treatment failure [2]. Despite this, antibiotic resistance sur-
veillance is needed to inform the empirical treatment guid-
ance used in an area for Test-and-Treat of patients with
dyspepsia. Such an antibiotic resistance surveillance service
is running in Germany [22].
This audit indicates that only two laboratories routinely
cultured significant numbers of gastric biopsy specimens for
H. pylori. It is important that these laboratories continue to be
supported to provide this service in order to maintain their
expertise and provide resilience. These laboratories could
provide a regional service for biopsy culture-based antibiotic
resistance surveillance. Alternatively, culture-based surveil-
lance could be provided centrally by the Gastrointestinal
Bacterial Reference Unit (GBRU).
Robust national surveillance is required to quantify the
burden of disease and microbiological surveillance is neces-
sary for monitoring antimicrobial resistance (AMR). Cur-
rently, the rates of AMR to first-line agents for empirical
treatment of H. pylori in England are not known, and we
do not know whether the threshold of resistance (20%) for
changing the combination has been reached.
Although it is not current practice, we recommend that
patient demographic data, including indication for the test,
should be routinely collected. As most laboratories perform
stool antigen tests, this demographic and clinical data could
be used to monitor H. pylori prevalence rates in different
sectors of the population. Furthermore, commercial assays
for detection of AMR in H. pylori in the stool specimens
are available and could prove to be a useful tool for rapid
detection of resistance to first-line agents like macrolides and
quinolones [23–25]. The use of multiple antibiotics for a pro-
longed period of time for the treatment of recurrentH. pylori
is an important aspect of community based antimicrobial
stewardship which needs to be addressed.
4.8. Strengths and Limitations. A strength of this audit is the
very high (71%) questionnaire return from the microbiology
department; it is possible that nonresponding laboratories do
not test forH. pylori on site. A limitation is that the question-
naire was not sent to gastroenterologists or histopathologists,
so it is not known which diagnostic services they provide.
As specific patient details are unknown, the laboratory
reported test positivity rates cannot be verified, and it is
unknown whether individuals were tested more than once
within the given time period. For future audits, it could be
recommended that duplicates are removed so that positivity
rates can be more rigorously followed.
5. Implications
The majority of laboratories comply with NICE guidance by
undertaking stool antigen tests. However, four laboratories
still perform serology as their first-line diagnostic test. As
very few laboratories are routinely performing culture of
gastric biopsy specimens to test for AMR, an English culture-
based surveillance system would probably need centralised
culture. However, a PCR based stool specimen surveillance
system could be possible. The feasibility of stool based sur-
veillance for monitoring prevalence would be simple to set
up with some extra clinical data collection. Further work
is required to determine the feasibility, cost-effectiveness,
sensitivity, and specificity of the stool based molecular assays
for detection of AMR. However, such a service would be
immensely helpful to monitor AMR to H. pylori in the
community setting.
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